Browsing by Author "Barahona, Isabel"
Now showing 1 - 10 of 16
Results Per Page
Sort Options
- Are there infectivity differences between HIV-2 and HIV-1 related to APOBEC3?Publication . Bandarra, Susana; Ribeiro, Ana Clara; Gonçalves, João; Barahona, Isabel
- Assessment of the Cavidi ExaVir load assay for monitoring plasma viral load in HIV-2-infected patientsPublication . Borrego, Pedro; Gonçalves, Maria Fátima; Gomes, Perpétua; Araújo, Lavínia; Moranguinho, Inês; Figueiredo, Inês Brito; Barahona, Isabel; Rocha, José; Mendonça, Claudino; Cruz, Maria Cesarina; Barreto, Jorge; Taveira, NunoHIV plasma viral load is an established marker of disease progression and of response to antiretroviral therapy, but currently there is no commercial assay validated for the quantification of viral load in HIV-2-infected individuals. We sought to make the first clinical evaluation of Cavidi ExaVir Load (version 3) in HIV-2- infected patients. Samples were collected from a total of 102 individuals living in Cape Verde, and the HIV-2 viral load was quantified by both ExaVir Load and a reference in-house real-time quantitative PCR (qPCR) used in Portugal in 91 samples. The associations between viral load and clinical prognostic variables (CD4 T cell counts and antiretroviral therapy status) were similar for measurements obtained using ExaVir Load and qPCR. There was no difference between the two methods in the capacity to discriminate between nonquantifiable and quantifiable HIV-2 in the plasma. In samples with an HIV-2 viral load quantifiable by both methods (n 27), the measurements were highly correlated (Pearson r 0.908), but the ExaVir Load values were systematically higher relative to those determined by qPCR (median difference, 0.942 log10 copies/ml). A regression model was derived that enables the conversion of ExaVir Load results to those that would have been obtained by the reference qPCR. In conclusion, ExaVir Load version 3 is a reliable commercial assay to measure viral load in HIV-2-infected patients and therefore a valuable alternative to the inhouse assays in current use.
- Characterization of CYP2C19*17 polymorphism in a Portuguese population sample relevant for proton pump inhibitor therapy : a pilot studyPublication . Ferraz, Adriana M. L.; Bandarra, Susana; Mascarenhas, Paulo; Barahona, Isabel; Martins, Rui; Ribeiro, Ana ClaraThe interindividual variability of Proton Pump Inhibitor (PPI) therapy results from the phenotype variability associated with the cytochrome P450 2C19 (CYP2C19) gene, namely the CYP2C19*17 allele. Our aim was to characterize patients’ genetic variability undergoing PPI therapy. A sample of 33 oral mucosa cells from Portuguese pharmacy patients was collected, followed by genotyping. The allelic frequencies of CYP2C19*1 (-806C) and CYP2C19*17 (-806T) were 71.2% and 28.8%, respectively. The genotypic frequencies for CYP2C19*1/*1 and CYP2C19*1/*17 were 42.4% and 57.6%, respectively, and 19 of these patients may have a Rapid Metabolizer (RM) phenotype pharmaceutical opinion letter, based on genetic evidence.
- Comparison of in-office and at-home tooth-whitening products cytotoxicityPublication . Pitz, Kristel; Bandarra, Susana; Mascarenhas, Paulo; Ribeiro, Ana Clara; Azul, Ana; Salema-Oom, Madalena; Barahona, Isabel
- Cytotoxicity of temperature-responsive cationic diblock copolymers in human cancer and non-cancer cells linesPublication . Bandarra, Susana; Mascarenhas, Paulo; Barahona, Isabel; Nyströmb, Bo; Calejo, Maria Teresa
- Effect of Diabetes Mellitus Type 2 on Salivary Glucose – A Systematic Review and Meta-Analysis of Observational StudiesPublication . Mascarenhas, Paulo; Fatela, Bruno; Barahona, Isabel"Background: Early screening of type 2 diabetes mellitus (DM) is essential for improved prognosis and effective delay of clinical complications. However, testing for high glycemia often requires invasive and painful blood testing, limiting its large-scale applicability. We have combined new, unpublished data with published data comparing salivary glucose levels in type 2 DM patients and controls and/or looked at the correlation between salivary glucose and glycemia/HbA1c to systematically review the effectiveness of salivary glucose to estimate glycemia and HbA1c. We further discuss salivary glucose as a biomarker for large-scale screening of diabetes or developing type 2 DM.
- Effect of Vif in doxorubicin treated breast cancer cellsPublication . Bandarra, Susana; Cipriano, Pedro; Gonçalves, João; Ribeiro, Ana Clara; Barahona, Isabel
- Evaluation of the cytotoxic potential of adhesives, with two on the market: Scotchbond Universal and Optibond Solo Plus, and an adhesive in the experimental phase: T1Publication . Santos, Sofia; Mascarenhas, Paulo; Bandarra, Susana; Ribeiro, Ana Clara; Maurício, Paulo; Barahona, IsabelIn vitro studies evaluating the cytotoxic potential of substances released from dental adhesives are lacking. The purpose of this study was to compare the cytotoxicity of the extracts of dental adhesives Scotchbond Universal and Optibond Solo Plus, and an adhesive in the experimental phase: T1. 3T3 mouse fibroblast cells and MG-63 osteoblast-like cells from human osteosarcoma were exposed for 24 h to serial extract dilutions. Cytotoxicity was determined using an MTT assay. For both cell lines, the cytotoxicity order obtained, of the unfiltered adhesive extracts, was T1 (less cytotoxic) < Optibond Solo Plus < Scotchbond Universal (most cytotoxic).
- High instantaneous inhibitory potential of Bictegravir and the new Spiro-β-Lactam BSS-730A for HIV-2 isolates from RAL-Naïve and RAL-Failing patientsPublication . Bártolo, Inês; Moranguinho, Inês; Gonçalves, Paloma; Diniz, Ana Rita; Borrego, Pedro; Martin, Francisco; Figueiredo, Inês; Gomes, Perpétua; Gonçalves, Fátima; Alves, Américo J. S.; Alves, Nuno; Caixas, Umbelina; Pinto, Inês V.; Barahona, Isabel; Melo, Teresa M. V. D. Pinho e; Taveira, NunoIntegrase inhibitors (INIs) are an important class of drugs for treating HIV-2 infection, given the limited number of drugs active against this virus. While the clinical efficacy of raltegravir and dolutegravir is well established, the clinical efficacy of bictegravir for treating HIV-2 infected patients has not been determined. Little information is available regarding the activity of bictegravir against HIV-2 isolates from patients failing raltegravir-based therapy. In this study, we examined the phenotypic and matched genotypic susceptibility of HIV-2 primary isolates from raltegravir-naïve and raltegravir-failing patients to raltegravir, dolutegravir, and bictegravir, and to the new spiro-β-lactam BSS-730A. The instantaneous inhibitory potential (IIP) was calculated to help predict the clinical activity of bictegravir and BSS-730A. Isolates from raltegravir-naïve patients were highly sensitive to all INIs and BSS-730A. Combined integrase mutations E92A and Q148K conferred high-level resistance to raltegravir, and E92Q and T97A conferred resistance to raltegravir and dolutegravir. The antiviral activity of bictegravir and BSS-730A was not affected by these mutations. BSS-730A displayed strong antiviral synergism with raltegravir. Mean IIP values at Cmax were similar for all INIs and were not significantly affected by resistance mutations. IIP values were significantly higher for BSS-730A than for INIs. The high IIP values of bictegravir and BSS-730A for raltegravir-naïve and raltegravir-resistant HIV-2 isolates highlight their potential value for treating HIV-2 infection. Overall, the results are consistent with the high clinical efficacy of raltegravir and dolutegravir for HIV-2 infection and suggest a promising clinical profile for bictegravir and BSS-730A.
- HIV Vif protein in docetaxel treatment of breast cancer cellsPublication . Cipriano, Pedro; Bandarra, Susana; Gonçalves, João; Ribeiro, Ana Clara; Barahona, Isabel